| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | UGT89C1 |
| Uniprot No | Q9LNE6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-435aa |
| 氨基酸序列 | MTTTTTKKPHVLVIPFPQSGHMVPHLDLTHQILLRGATVTVLVTPKNSSYLDALRSLHSPEHFKTLILPFPSHPCIPSGVESLQQLPLEAIVHMFDALSRLHDPLVDFLSRQPPSDLPDAILGSSFLSPWINKVADAFSIKSISFLPINAHSISVMWAQEDRSFFNDLETATTESYGLVINSFYDLEPEFVETVKTRFLNHHRIWTVGPLLPFKAGVDRGGQSSIPPAKVSAWLDSCPEDNSVVYVGFGSQIRLTAEQTAALAAALEKSSVRFIWAVRDAAKKVNSSDNSVEEDVIPAGFEERVKEKGLVIRGWAPQTMILEHRAVGSYLTHLGWGSVLEGMVGGVMLLAWPMQADHFFNTTLIVDKLRAAVRVGENRDSVPDSDKLARILAESAREDLPERVTLMKLREKAMEAIKEGGSSYKNLDELVAEMCL |
| 预测分子量 | 50.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UGT89C1重组蛋白的模拟参考文献示例(仅供参考，具体文献需通过学术数据库验证)：
---
1. **文献名称**: *Heterologous Expression and Functional Characterization of Arabidopsis UGT89C1 as a Flavonoid Glucosyltransferase*
**作者**: Lim EK, Davis BG, Bowles DJ
**摘要**: 本研究在昆虫细胞中重组表达了拟南芥UGT89C1蛋白，证实其催化类黄酮(如槲皮素)的葡萄糖基化反应，并通过酶动力学分析揭示了其对特定羟基位点的底物选择性，为植物次生代谢研究提供依据。
2. **文献名称**: *Substrate Specificity and Structural Insights of Recombinant UGT89C1 through Crystallographic Analysis*
**作者**: Jones PR, Williams GJ, Thibodeaux CJ
**摘要**: 通过大肠杆菌表达系统纯化UGT89C1重组蛋白，结合X射线晶体学解析其三维结构，阐明了活性口袋的关键氨基酸残基，并验证了其对芳香族化合物的催化机制，为理性设计糖基化酶奠定基础。
3. **文献名称**: *UGT89C1 in Drug Metabolism: Recombinant Expression and In Vitro Activity Screening*
**作者**: Mackenzie PI, Hu DG, Gardner-Stephen DA
**摘要**: 在HEK293细胞中表达人源UGT89C1重组蛋白，筛选其对多种药物(如非甾体抗炎药)的葡萄糖醛酸化活性，发现其对特定底物具有高效催化能力，提示其在药物解毒中的潜在作用。
---
**注意**：上述文献为示例，实际研究需通过PubMed、Web of Science等平台检索。若UGT89C1相关研究较少，可扩展至同一家族其他亚型(如UGT89A/B)或调整物种关键词。
**Background of UGT89C1 Recombinant Protein**
UGT89C1. a member of the uridine diphosphate (UDP)-glycosyltransferase (UGT) superfamily, plays a critical role in the conjugation of small lipophilic molecules with glycosyl groups, facilitating their detoxification, solubility, and excretion. UGT enzymes are pivotal in phase II metabolism, influencing the bioavailability and clearance of endogenous compounds (e.g., hormones, bilirubin) and xenobiotics (e.g., drugs, environmental toxins). UGT89C1. specifically, is implicated in the glucuronidation of diverse substrates, though its precise physiological and pharmacological roles remain under investigation.
Recombinant UGT89C1 protein is engineered via heterologous expression systems, such as *E. coli* or mammalian cell lines, to enable functional and structural studies. Its production allows researchers to explore substrate specificity, catalytic mechanisms, and interactions with cofactors or inhibitors in controlled settings. This recombinant tool is vital for drug development, as UGT polymorphisms or altered expression can lead to interindividual variability in drug metabolism, toxicity, or therapeutic failure.
Studies leveraging UGT89C1 recombinant protein contribute to understanding its role in diseases linked to metabolic dysregulation, such as cancer or liver disorders. Additionally, structural analyses (e.g., X-ray crystallography, cryo-EM) using the recombinant protein help elucidate active-site architecture and guide rational drug design.
The protein’s applications extend to pharmacogenomics, toxicology, and personalized medicine, where insights into UGT89C1 activity aid in optimizing drug regimens and minimizing adverse effects. Quality-controlled batches of recombinant UGT89C1. validated via SDS-PAGE, mass spectrometry, and activity assays, ensure reproducibility in research and translational studies. Overall, UGT89C1 recombinant protein serves as a cornerstone for advancing metabolic enzymology and therapeutic innovation.
×
